Vitruvian Partners LLP Maxcyte, Inc. Transaction History
Vitruvian Partners LLP
- $257 Million
- Q3 2024
A detailed history of Vitruvian Partners LLP transactions in Maxcyte, Inc. stock. As of the latest transaction made, Vitruvian Partners LLP holds 5,043,356 shares of MXCT stock, worth $20.7 Million. This represents 7.62% of its overall portfolio holdings.
Number of Shares
5,043,356
Previous 5,043,356
-0.0%
Holding current value
$20.7 Million
Previous $19.8 Million
0.76%
% of portfolio
7.62%
Previous 5.8%
Shares
3 transactions
Others Institutions Holding MXCT
# of Institutions
124Shares Held
65.6MCall Options Held
1KPut Options Held
2K-
Cadian Capital Management, LP New York, NY8.19MShares$33.7 Million1.63% of portfolio
-
Black Rock Inc. New York, NY8.14MShares$33.5 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.78MShares$23.7 Million0.0% of portfolio
-
Morgan Stanley New York, NY4.82MShares$19.8 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny4.19MShares$17.2 Million0.01% of portfolio
About MAXCYTE, INC.
- Ticker MXCT
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 101,724,000
- Market Cap $418M
- Description
- MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expr...